Fig. 4: The effects of Azacitidine and Tiragolumab on various cell lines and their impact on leukemia in a mouse model.

The expression levels of TIGIT in Kasumi-1, OCI-AML3, and MOLM13 cell lines treated with DMSO or Azacitidine. The upper panel (a) displays the quantitative data, while the lower panel (b) shows the Western blot analysis. c The methylation status of the TIGIT promoter region in these three cell lines. Green circles indicate methylated regions, while white circles indicate unmethylated regions. d The cell viability of Kasumi-1, OCI-AML3, and MOLM13 cell lines under different treatment conditions, including mock, UCB-NK, UCB-NK with Azacitidine, UCB-NK with Tiragolumab, and UCB-NK with both Azacitidine and Tiragolumab. e The cell viability under conditions involving high and low NK cells, with and without treatments. The synergistic effect of tiragolumab plus azacitidine was calculated by CompuSyn software. f A schematic illustration of the experimental setup for the mouse model, showing the process of leukemia cell injection, infection, and treatment with different compounds. g Kaplan-Meier survival curve depicting the survival rates of mice over time after leukemia cell injection, comparing different treatment groups (vehicle, TIGIT, Azacitidine, and Azacitidine + TIGIT). h Photographs of spleens from treated mice, showing the physical changes due to different treatments. i The distribution of cells in peripheral blood (PB), bone marrow (BM), and spleen (SP) under different treatment conditions by Flow cytometry. j The percentage of leukemia cells in PB, BM, and SP under different treatment conditions.